戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              IL-1 beta abundance was determined by enzyme-linked immu
2                                              IL-1 beta activated phosphatidylinositol (PI) 3-kinase,
3                                              IL-1 beta also induced cartilage proteoglycan degradatio
4                                              IL-1 beta and ATRA induced TG transamidation activity an
5                                              IL-1 beta and CDCA reduced CYP7A1 but induced c-Jun mess
6                                              IL-1 beta and TNF alpha stimulated the transcript (7-8-f
7                                              IL-1 beta antagonists or proteasome inhibitors might inc
8                                              IL-1 beta expression was elevated in lung macrophages ex
9                                              IL-1 beta expression was examined in lung macrophages ex
10                                              IL-1 beta greatly increased the levels of FGF-2 mRNA in
11                                              IL-1 beta has emerged as a prime candidate underlying th
12                                              IL-1 beta induced robust expression of COX-2 and PGE(2)
13                                              IL-1 beta initially induced nuclear accumulation of FGF-
14                                              IL-1 beta mRNA also increased after infection and IL-1 b
15                                              IL-1 beta release and cell permeability are suppressed b
16                                              IL-1 beta resulted in a decrease in HNF-4 alpha levels i
17                                              IL-1 beta significantly decreased glucose-stimulated ins
18                                              IL-1 beta stimulated the expression of C/EBP beta and -d
19                                              IL-1 beta treatment of cultured primary rat hepatocytes
20                                              IL-1 beta treatment of primary hepatocytes reduced Mrp2
21                                              IL-1 beta up-regulated GCLC expression (10 ng/ml IL-1 be
22                                              IL-1 beta, the most potent inducer of COX-2, also result
23                                              IL-1 beta-converting enzyme (ICE; caspase-1) is the intr
24                                              IL-1 beta-induced production of COX-2 protein and PGE(2)
25                                              IL-1 beta-mediated degradation of cartilage proteoglycan
26 ytokines transforming growth factor-beta(1), IL-1 beta, and IL-4 in the heart.
27 ytokines transforming growth factor-beta(1), IL-1 beta, and IL-4 in the hearts of IFN-gamma-deficient
28 ease of the proinflammatory cytokines IL-18, IL-1 beta, and IFN-gamma from total colon cultures.
29 , IFN-gamma-inducible protein-10, IL-1alpha, IL-1-beta, IL-1Ralpha, IL-18, IL-6, and IFN-gamma), or h
30 decreased when DCs were incubated with IL-4, IL-1 beta, TNF alpha, and an agonistic CD40 antibody (ma
31          The mRNA expression levels of IL-6, IL-1 beta, and iNOS were significantly increased in the
32 ry cytokines and their mRNAs measured (IL-6, IL-1 beta, IL-8, and tumor necrosis factor alpha), IL-8
33  insulin secretion (control, 123.8 +/- 17.7; IL-1 beta, 40.2 +/- 3.9 microunits/ml insulin/islet).
34 te for neutralized IL-1 beta, and additional IL-1 beta did not compensate for neutralized IL-1 alpha,
35 98059) or p38 MAPK (SB203580) did not affect IL-1 beta-mediated suppression of Ntcp gene expression,
36 ight increase in COX-2 mRNA expression after IL-1 beta treatment.
37 s assessed (i.e., interleukin [IL]-1 alpha , IL-1 beta , IL-2, IL-4, IL-6, IL-10, interferon- gamma ,
38  cytokines interleukin-1 alpha (IL-1 alpha), IL-1 beta, and IL-6 or of the microglial marker F4/80 at
39 tor alpha, interleukin-1 alpha (IL-1 alpha), IL-1 beta, CCL5, IL-6, and KC.
40 se include interleukin-1 alpha (IL-1 alpha), IL-1 beta, IL-6, IL-8, and tumor necrosis factor alpha.
41            The concentrations of IL-1 alpha, IL-1 beta (precursor and mature forms), and IL-1 recepto
42 in-12 [IL-12], gamma interferon, IL-1 alpha, IL-1 beta), CC chemokines (CC chemokine ligand 3 [CCL3]/
43       Upregulation of IFN-gamma, IL-1 alpha, IL-1 beta, and IL-8 and increased severity of inflammato
44       Upregulation of IFN-gamma, IL-1 alpha, IL-1 beta, and IL-8 and marked hyperplasia of secondary
45 is, prompted the hypothesis that IL-1 alpha, IL-1 beta, and IL-RA may help regulate human IgG2 respon
46 ytokines regulated by NF-kappaB (IL-1 alpha, IL-1 beta, IL-10, and IFN-gamma).
47 feron (IFN-gamma), interleukin (IL)-1 alpha, IL-1 beta, IL-4, IL-6, IL-8, IL-10, and IL-12 p40 and hi
48  expression levels of TNF-alpha, IL-1 alpha, IL-1 beta, VEGF-A, VEGF-C, and VEGFR2.
49 imulated significant increases in TNF alpha, IL-1 beta, and IL-6 due to the absence of estrogen.
50 KO) mice produced lower levels of TNF-alpha, IL-1 beta, and IFN-gamma than did wild-type (WT) mice.
51 nterleukin-1 beta, and IFN-gamma (TNF-alpha, IL-1 beta, and IFN-gamma) function synergistically for i
52 ensitive bioassays to measure net TNF-alpha, IL-1 beta, and IL-6 activity.
53 of inflammatory mediators such as TNF-alpha, IL-1 beta, and IL-6, vs late stage infections, which are
54  MIP-1 beta, IL-8) and cytokines (TNF-alpha, IL-1 beta, IL-6) from human dendritic cells and macropha
55  to be dependent on the cytokines TNF-alpha, IL-1 beta, IL-6, and IFN-gamma, nor is it dependent on t
56 s inflammatory stimuli, including TNF-alpha, IL-1 beta, IL-6, and LPS.
57 pression of cytokines, IFN-gamma, TNF-alpha, IL-1 beta, IL-6, IL-4, IL-10, and chemokines, MIP-1, MIP
58 on of pro-inflammatory mediators, TNF-alpha, IL-1 beta, IL-6, MMP-2 and MMP-9 in HCECs exposed to hyp
59 that A beta-induced expression of TNF-alpha, IL-1 beta, MCP-1, IL-8, and MIP-1 beta was abrogated in
60 proinflammatory cytokines such as TNF-alpha, IL-1 beta, or other host factors.
61                                     Although IL-1 beta and RANTES mRNA could be detected in the splee
62                      The results revealed an IL-1 beta-responsive element located between -2138 and -
63 s of IL-10 (P=.003), IFN-gamma (P=.007), and IL-1 beta (P=.05) than children with UM.
64 factors, and the inflammasome, caspase-1 and IL-1 beta were critical for the recruitment of microglia
65 s of MCP-1 following stimulation by IL-2 and IL-1 beta; RA FLS produced significantly more MCP-1 than
66 rane permeability, caspase-1 activation, and IL-1 beta release without cell cytotoxicity.
67 ts positively correlated with IL-1 alpha and IL-1 beta and with the proportions of Selenomonas, Prevo
68                               IL-1 alpha and IL-1 beta appear to have critical and non-redundant role
69                               IL-1 alpha and IL-1 beta are important inhibitors of hair growth in vit
70 eric symptoms, suggesting that TNF-alpha and IL-1 beta are not key mediators of diarrhea in human cry
71 NA viruses, is known to induce TNF-alpha and IL-1 beta in a variety of cells.
72 an either antibody alone, and IL-1 alpha and IL-1 beta in combination appeared to work additively in
73 g that dsRNA treatment induces TNF-alpha and IL-1 beta in human lung epithelial cells via two differe
74 CL-9, CCL-3, CCL-4, IFN-gamma, TNF-alpha and IL-1 beta in sIBM muscle compared to PM, DM and controls
75 eduction in lung and BAL fluid TNF-alpha and IL-1 beta protein and/or mRNA levels.
76 ctin expression in response to TNF-alpha and IL-1 beta was developed to measure the ability of aPDT t
77 um levels of tumor necrosis factor-alpha and IL-1 beta were significantly depressed in M40401-treated
78 duced expression of cytokines (TNF-alpha and IL-1 beta) and chemokines (MCP-1, IL-8, and MIP-1 beta)
79 sibly through an inhibition of TNF-alpha and IL-1 beta, which are potent neutrophil recruiting mediat
80 inflammatory cytokines such as TNF-alpha and IL-1 beta.
81 ecrease in local production of TNF-alpha and IL-1 beta.
82 Increased expression of iNOS, TNF-alpha, and IL-1 beta were observed in the affected white matter, co
83 mRNA expression of cytokines (TNF-alpha, and IL-1 beta) and chemokines (monocyte chemoattractant prot
84  macrophage inflammatory protein 1 beta, and IL-1 beta levels were significantly upregulated in the i
85           Our observations that blebbing and IL-1 beta release are dissociable suggest these events o
86 ammatory cytokines TNF-alpha, IFN-gamma, and IL-1 beta.
87 beta mRNA also increased after infection and IL-1 beta protein was synthesized, but it remained intra
88 mined as release of the CXC chemokine KC and IL-1 beta, was inhibited by the more selective MC3-R ago
89 appa B alpha degradation elicited by LPS and IL-1 beta but not that stimulated by tumor necrosis fact
90 3-kinase is an important mediator of LPS and IL-1 beta signaling leading to NF-kappa B activation in
91 d Akt kinase activity in response to LPS and IL-1 beta.
92 appa B luciferase activity evoked by LPS and IL-1 beta.
93 the exogenous proinflammatory agents LPS and IL-1 beta.
94 g TNF, phorbol ester, okadaic acid, LPS, and IL-1 beta.
95 cate that FADD negatively regulates LPS- and IL-1 beta-induced NF-kappa B activation and that this re
96                     Mrp2 down-regulation and IL-1 beta up-regulation were observed in liver after BDL
97 re, combinations of anti-IL-1 alpha and anti-IL-1 beta were more inhibitory than either antibody alon
98          Both inflammatory cytokines such as IL-1 beta and bacterial constituents may be responsible
99                                      Because IL-1 beta function involves nuclear factor kappa B (NF-k
100 rences, the induction of interleukin-1 beta (IL-1 beta) and intracellular adhesion molecule-1 was mod
101 ed significant levels of interleukin-1 beta (IL-1 beta) but not endothelin-1 or tumor necrosis factor
102           We report that interleukin-1 beta (IL-1 beta) elicits PECAM-1-dependent transmigration that
103 opolysaccharide (LPS) or interleukin-1 beta (IL-1 beta) for 0, 2, 4, 6, or 8 h.
104 ro-inflammatory mediator interleukin-1 beta (IL-1 beta) in their joints, suggesting inefficient activ
105                          Interleukin-1 beta (IL-1 beta) is a cytokine and a member of the beta-trefoi
106                          Interleukin-1 beta (IL-1 beta) is a cytokine whose levels are increased in v
107                          Interleukin 1 beta (IL-1 beta) is a key cytokine in the inflammatory respons
108 proinflammatory cytokine interleukin-1 beta (IL-1 beta) mediates COX-2 expression in HT-29 human colo
109  activity in response to interleukin-1 beta (IL-1 beta) or lipopolysaccharide (LPS) + interferon-gamm
110 bovis BCG vaccination on interleukin-1 beta (IL-1 beta) or regulated-upon-activation, normally T-cell
111 Significant variation in interleukin-1 beta (IL-1 beta) protein secretion between subjects has been o
112 xycholic acid (CDCA) and interleukin-1 beta (IL-1 beta) regulation of human CYP7A1 gene expression vi
113 lpha:RXR alpha, and that interleukin 1 beta (IL-1 beta) repressed promoter activity via this element.
114 in treatment of rats and interleukin-1 beta (IL-1 beta) treatment of liver-derived HepG2 cells leads
115 actor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), and IL-6 from human peripheral blood mononuc
116 lpha receptors I and II; interleukin 1 beta (IL-1 beta), IL-1 beta receptor antagonist, and soluble I
117 ndent antigen and normal interleukin-1 beta (IL-1 beta), IL-6, and TNF production after LPS treatment
118                Levels of interleukin-1 beta (IL-1 beta), IL-6, IL-8, and tumor necrosis factor alpha
119  interferon (IFN-alpha), interleukin-1 beta (IL-1 beta), IL-8, IL-12, MIP-1 alpha, and RANTES but not
120 pression is repressed by interleukin 1 beta (IL-1 beta).
121 opolysaccharide (LPS) or interleukin-1 beta (IL-1 beta).
122 er it is up-regulated by interleukin-1 beta (IL-1 beta).
123 e band was identified as interleukin-1 beta (IL-1 beta).
124 actor alpha (TNF-alpha), interleukin 1 beta (IL-1 beta-6, gamma interferon (IFN-gamma), MIP-1 alpha M
125 ristate 13-acetate (PMA), interleukin-1 beta(IL-1 beta), or lipopolysaccharide (LPS).
126 rs I and II; interleukin 1 beta (IL-1 beta), IL-1 beta receptor antagonist, and soluble IL-1 receptor
127 he following: 1) a novel correlation between IL-1 beta secretion and the release of the MHC-II membra
128 ve JNK expression plasmid completely blocked IL-1 beta-mediated suppression.
129 e stability of COX-2 mRNA was not altered by IL-1 beta treatment.
130 ucose-stimulated insulin secretion caused by IL-1 beta.
131 olved in activation of NF-kappa B complex by IL-1 beta stimulation.
132 ctivation and cytokine expression induced by IL-1 beta and lipopolysaccharide.
133 esistant to NF-kappa B activation induced by IL-1 beta.
134 the repression of NF-kappa Bp50 induction by IL-1 beta.
135 s and collagen type II that are inhibited by IL-1 beta.
136 0 protein production in conditioned media by IL-1 beta and TNF-alpha.
137                   ProIL-1 beta processing by IL-1 beta-converting enzyme (ICE) and the subsequent rel
138 tion in pathologic calcification promoted by IL-1 beta and ATRA.
139  by which CD-RAP expression is suppressed by IL-1 beta, deletion constructs of the mouse CD-RAP promo
140 and -11 were dose dependently upregulated by IL-1 beta and TNF-alpha, whereas MMP-8 and -14 and tissu
141 nflammatory colonic and plasma IL-6, colonic IL-1 beta and higher levels of colonic IL-17 when compar
142                               In conclusion, IL-1 beta and CDCA inhibit HNF4 alpha but induce c-Jun,
143  these cells to the proinflammatory cytokine IL-1 beta increased the expression of the NK-1R gene at
144 inflammatory molecules, such as the cytokine IL-1 beta, may have beneficial and protective effects.
145 ated with the release of all four cytokines (IL-1 beta [R(2) = 0.382; P = 0.006], IL-6 [R(2) = 0.393;
146 red the levels of proinflammatory cytokines (IL-1 beta, TNF-alpha, and S100B), the chemokine CCL2, mi
147 tiate that the observed NF-kappa B-dependent IL-1 beta induction of the human NK-1R gene is regulated
148 vities of IL-1 beta were further determined; IL-1 beta altered the shape of CECs from polygonal to fi
149 scription, perhaps as a result of diminished IL-1 beta, IL-6, and IFN-gamma levels.
150 ha ligands (clofibrate and WY14643) enhanced IL-1 beta-induced COX-2 expression in human astrocytes a
151  bodies that contain exosomes with entrapped IL-1 beta, caspase-1, and other inflammasome components.
152 olunteers expressed TNF-alpha; 14% expressed IL-1 beta.
153                                    Following IL-1 beta or TGF-beta(1) stimulation, HMMP13 mRNA levels
154 little effect on the kinetics of folding for IL-1 beta.
155 LISA analysis showed that protein levels for IL-1 beta, macrophage-inflammatory protein 2, and macrop
156 tion was essential for TNF-alpha but not for IL-1 beta expression.
157 lts demonstrate a possible adaptive role for IL-1 beta-driven neuroinflammation in AD and may help ex
158 interleukin-6 (IL-6), and IL-8; and weak for IL-1 beta and monocyte chemotactic peptide 1 (MCP-1).
159    The total amount and concentration of GCF IL-1 beta, IL-4, IL-10, and TNF-alpha were similar in RA
160                                          How IL-1 beta signaling leads to reduced RXR:RAR nuclear bin
161 , including interleukin (IL)-1 alpha (IL1A), IL-1 beta (IL1B), IL8, RANTES, colony stimulating factor
162 PDTC, resulted in dose-dependent decrease in IL-1 beta-induced COX-2 gene expression and PG productio
163 ne contribute to the observed differences in IL-1 beta protein secretion.
164 anscription of NF-kappa B-dependent genes in IL-1 beta-induced rheumatoid arthritis-derived synovial
165 h is atypical for destabilizing mutations in IL-1 beta.
166  tuberculosis showed 75 to 90% reductions in IL-1 beta expression and 25 to 60% reductions in RANTES
167 atment potently and functionally inactivated IL-1 beta and TNF-alpha.
168 sion of proinflammatory cytokines, including IL-1 beta, macrophage-inflammatory protein-2, and TNF-al
169 vealed that inflammatory mediators including IL-1 beta co-localized to beta-amyloid depositions withi
170 several key inflammatory mediators including IL-1 beta, IL-8, and tumor necrosis factor-alpha are up-
171 ibitors Fasudil and Y-27632, but ATP-induced IL-1 beta release was unaffected.
172 ibute to observed differences in LPS-induced IL-1 beta protein secretion.
173 ated with a 2-3-fold increase in LPS-induced IL-1 beta protein secretion.
174 h a panel of melanocortin peptides inhibited IL-1 beta release and PMN accumulation elicited by urate
175 umin, but not PD98059 or SB203580, inhibited IL-1 beta-mediated suppression of nuclear RXR:RAR bindin
176 n astrocytes and microglia, while inhibiting IL-1 beta plus IFN-gamma induction of iNOS in astrocytes
177 EP4(-/-) animals produced significantly less IL-1 beta and IL-6 than control samples.
178 t untreated endothelial cells express little IL-1 beta or TNF-alpha, but incubation with TGF-beta res
179 produced no detectable IL-18, fourfold lower IL-1 beta, and 20-30% less IL-1 alpha than macrophages f
180                            In contrast, LPS, IL-1 beta, and PMA each upregulated IL-8.
181 ema, pulmonary neutrophil accumulation, lung IL-1 beta, macrophage-inflammatory protein-2, and TNF-al
182 se mice showed significant increases in lung IL-1 beta mRNA expression, but not the protein, compared
183 2 mRNA in a time- and dose-dependent manner; IL-1 beta stimulated expression of all isoforms of FGF-2
184 ofluorescent staining for IL-1 alpha, mature IL-1 beta, and IL-1Ra was observed in a significantly gr
185 , the concentration of IL-1 alpha and mature IL-1 beta in the tear fluid was increased, and the conce
186 mmatory forms of IL-1 (IL-1 alpha and mature IL-1 beta) and a decrease in the biologically inactive p
187  < 0.01 for IL-1 alpha, P < 0.009 for mature IL-1 beta, and P < 0.05 for IL-1Ra).
188 e (ICE) and the subsequent release of mature IL-1 beta are highly regulated events in the monocyte/ma
189 t initiates cleavage and secretion of mature IL-1 beta.
190 hondrocytes with the osteoarthritis mediator IL-1 beta, with the all-trans form of retinoic acid (ATR
191  (CNV) was induced by suture or micropellet (IL-1 beta, VEGF-A) placement.
192 ence of 100 units/ml IFN-gamma plus 10 ng/ml IL-1 beta for 48 h.
193  beta up-regulated GCLC expression (10 ng/ml IL-1 beta, 3.76 +/- 0.86; 100 ng/ml IL-1 beta, 4.22 +/-
194 10 ng/ml IL-1 beta, 3.76 +/- 0.86; 100 ng/ml IL-1 beta, 4.22 +/- 0.68-fold control) via the p38 form
195 sed reactive oxygen species levels (10 ng/ml IL-1 beta, 5.41 +/- 1.8-fold control).
196 H/GSSG ratio (control, 7.1 +/- 0.1; 10 ng/ml IL-1 beta, 8.0 +/- 0.5; 100 ng/ml IL-1 beta, 8.2 +/- 0.5
197 ; 10 ng/ml IL-1 beta, 8.0 +/- 0.5; 100 ng/ml IL-1 beta, 8.2 +/- 0.5-fold control; p < 0.05).
198 L-1 alpha did not compensate for neutralized IL-1 beta, and additional IL-1 beta did not compensate f
199                  Dexamethasone, neutralizing IL-1 beta antibody, or the selective COX-2 inhibitor, SC
200  dose-dependent manner, whereas neutralizing IL-1 beta antibody, neutralizing antibody to FGF-2, and
201 nstitute the major pathways for nonclassical IL-1 beta secretion from ATP-stimulated murine macrophag
202 sociated with induction of TNF-alpha but not IL-1 beta expression.
203 sRNA-induced elevations in TNF-alpha but not IL-1 beta mRNA in epithelial cells.
204 B) signaling pathways blocked the ability of IL-1 beta to induce COX-2 mRNA.
205 to FGF-2, and LY294002 blocked the action of IL-1 beta.
206 ivity of MMP-9, a physiological activator of IL-1 beta, was significantly elevated in the tear fluid
207                     Biological activities of IL-1 beta were further determined; IL-1 beta altered the
208  LY294002 hampered the induction activity of IL-1 beta.
209  in conjunction with biochemical analyses of IL-1 beta release.
210 V had significantly higher concentrations of IL-1 beta in vaginal wash samples than did women with no
211 d MHC-II; and 3) mechanistic dissociation of IL-1 beta export from either secretory lysosome exocytos
212                                The effect of IL-1 beta and TNF alpha on the expression and secretion
213 c inhibitor blocked the inhibitory effect of IL-1 beta on HNF4 alpha expression and CYP7A1 reporter a
214 he islet and prevents the adverse effects of IL-1 beta on glucose-induced insulin secretion, islets w
215 ts the beta cell from the adverse effects of IL-1 beta.
216 (JNK), completely ameliorated the effects of IL-1 beta.
217 ase-1 in triggering the cotemporal export of IL-1 beta and MHC-II; and 3) mechanistic dissociation of
218 optotic cells or FBS, elicited expression of IL-1 beta by NOD macrophages is markedly reduced compare
219     An interesting feature in the folding of IL-1 beta, shared with some other members of the same to
220 t induce TNF-alpha and was a weak inducer of IL-1 beta, IL-6, macrophage inflammatory protein 1 alpha
221 fering RNA did not limit NO-np inhibition of IL-1 beta secretion from monocytes, and neither TNF-alph
222 ells are treated with TGF-beta and levels of IL-1 beta and TNF-alpha determined.
223 lpha expression but induces normal levels of IL-1 beta, TNF-alpha, and IFN-gamma, causes greatly redu
224  compensated for by the endogenous levels of IL-1 beta, TNF-alpha, or IFN-gamma that are produced in
225 with high IgG2 levels had elevated levels of IL-1 beta.
226 Our findings suggest an alternative model of IL-1 beta release that may involve the P2X7R-induced for
227 in which local hippocampal overexpression of IL-1 beta in an Alzheimer disease (AD) transgenic mouse
228 ular protease that cleaves the precursors of IL-1 beta and IL-18 into active cytokines.
229 atory caspase-1, which cleaves precursors of IL-1 beta and IL-18, were protected against ischemic acu
230                              The presence of IL-1 beta in vaginal wash samples was associated with >3
231 e findings show that caspase-1 processing of IL-1 beta and IL-18 is not absolutely required for media
232                               The release of IL-1 beta is a tightly controlled process that requires
233 monocytes leads to maturation and release of IL-1 beta via the P2X(7) receptor.
234 sma membrane organization and the release of IL-1 beta, we generated time-lapse movies of ATP-stimula
235 ity) and simultaneously initiates release of IL-1 beta.
236 eptor NALP3, which results in the release of IL-1 beta.
237 e administration of LPS may be the result of IL-1 beta-induced degradation, and likely contributes to
238 plasma membrane morphology, and secretion of IL-1 beta from LPS-primed macrophages.
239 or association with LPS-induced secretion of IL-1 beta protein as measured by an ex vivo blood stimul
240 ulation of ICE activation and suppression of IL-1 beta processing and release.
241 tinguish the role of IL-1 alpha from that of IL-1 beta during this process.
242 t is characterized by the underexpression of IL-1 beta and multiple other cytokines.
243 5 seconds), we made ten sequence variants of IL-1 beta (L10A, T9Q, T9G, C8S, C8A, N7G, N7D, L6A, R4P,
244  APPswe/PS1dE9 mouse model of AD, 4 weeks of IL-1 beta overexpression led to a reduction in amyloid p
245 hat BCG vaccination has a positive effect on IL-1 beta and RANTES mRNA expression by host cells in a
246         Similarly, a milder effect of ETA on IL-1 beta and IL-18 was observed for IRF-1 KO than for W
247 udying the effects of isoprenoid shortage on IL-1 beta generation, we identified a new inflammasome a
248  ATP concentrations > or = 3 mM, but optimal IL-1 beta release occurred at 1 mM ATP.
249 or with IL-1RA or neutralizing IL-1 alpha or IL-1 beta with specific antibody dramatically suppressed
250  macrophage inflammatory protein 1 alpha, or IL-1 beta.
251 bodies or recombinant IL-1RA, IL-1 alpha, or IL-1 beta.
252 d significantly suppressed suture-induced or IL-1 beta-induced hemangiogenesis (HA) but not lymphangi
253 tion of NF-kappa B elicited by either LPS or IL-1 beta.
254 inocytes appeared to be unaffected by LPS or IL-1 beta.
255 homology to MyD88, failed to inhibit LPS- or IL-1 beta-induced Akt activity.
256 but did not effect either the spontaneous or IL-1 beta-induced secretion of MCP-1.
257 lysis using probes generated from guinea pig IL-1 beta or RANTES cDNA.
258 mal quantities of the leaderless polypeptide IL-1 beta, but sequential treatment of wild-type, but no
259 ion was upregulated as early as 2 hours post IL-1 beta challenge and was accompanied by a sustained P
260 n the concentration of IL-1 alpha, precursor IL-1 beta, and IL-1Ra in reflex tear fluid, indicating t
261 rease in the biologically inactive precursor IL-1 beta in tear fluid.
262 ncreased, and the concentration of precursor IL-1 beta was decreased in patients with MGD (P < 0.05,
263  0.17, P < 0.02) and the mature-to-precursor IL-1 beta ratio (r(2) = 0.46, P < 0.001).
264 face may be one mechanism by which precursor IL-1 beta is cleaved to the mature, biologically active
265             In response to ATP, however, pro-IL-1 beta produced by the P2X(7)R(-/-) cells is not exte
266 uires induced synthesis of the precursor pro-IL-1 beta and a second stimulus that initiates cleavage
267 lain the rapid export of caspase-1-processed IL-1 beta from monocytes/macrophages in response to acti
268 eficient mice had diminished proinflammatory IL-1 beta , IL-13, and IL-33 chemokines production, whil
269 We conclude that endogenous LL37 may promote IL-1 beta processing and release via direct activation o
270 h ATP as a second stimulus potently promotes IL-1 beta maturation and release via P2X(7) receptor act
271 terleukin (IL)-18, a member of the pyrogenic IL-1 beta family.
272  or longer, limiting the activity of soluble IL-1 beta and TNF-alpha in the lungs at the onset of ARD
273 tion of these mechanisms to P2X7R-stimulated IL-1 beta secretion in primary bone marrow-derived macro
274 scribe a transgenic mouse model of sustained IL-1 beta overexpression that was capable of driving rob
275                  These data demonstrate that IL-1 beta induces COX-2 expression in HT-29 cells throug
276                 This study demonstrated that IL-1 beta and TNF-alpha upregulate collagenases (MMP-1,
277  assay on nuclear extracts demonstrated that IL-1 beta induced NF-kappa B DNA binding activity in HT-
278           These novel findings indicate that IL-1 beta, which is rapidly induced in response to T. cr
279 oprecipitation and ChIP assays revealed that IL-1 beta and CDCA reduced HNF4 alpha bound to the CYP7A
280              These observations suggest that IL-1 beta takes part in endothelial to mesenchymal trans
281                                          The IL-1 beta mRNA levels peaked as soon as 1 h after PPD st
282 COX-2 inhibitor, SC-236, attenuated both the IL-1 beta-induced PGE(2) production and cartilage proteo
283                             Furthermore, the IL-1 beta pathway was essential for the microglial synth
284 and -delta may play an important role in the IL-1 beta-induced repression of cartilage-specific prote
285                                         This IL-1 beta-induced decrease was likely caused by degradat
286                   Exposure of these cells to IL-1 beta or overexpression of NF-kappa B cDNAs resulted
287               In human myotubes, exposure to IL-1 beta caused upregulation of APP with subsequent int
288 greatly stimulated after a 5-min exposure to IL-1 beta.
289 P motif abolished the inhibitory response to IL-1 beta.
290             NF-kappaB nuclear translocation, IL-1 beta and TNF-alpha gene expression, and protein con
291 hages was determined using recombinant trout IL-1 beta, where a clear induction was apparent by 2 h a
292 a in primary sinus epithelial cells, whereas IL-1 beta, IL-4, IL-13, and IL-17 did not influence IL-3
293 -2-produced PGE(2) is one mechanism by which IL-1 beta modulates cartilage proteoglycan degradation i
294                Treatment of HT-29 cells with IL-1 beta induced expression of COX-2 mRNA and protein i
295 RA- and OA-derived synovial fibroblasts with IL-1 beta and TNF alpha further suggests that the expres
296 l epithelial cell cultures were treated with IL-1 beta or TNF-alpha, with or without their correspond
297  human corneal epithelial cells treated with IL-1 beta, TNF-alpha, and doxycycline, a medication used
298 oplasty and cultured ex vivo with or without IL-1 beta and COX inhibitors.
299 nto rat chondrocytes treated with or without IL-1 beta.
300 ature of this slow step in the folding of WT IL-1 beta (tau(1)=45 seconds), we made ten sequence vari

 
Page Top